INNOVA CAPTAB LIMITED
Plot No. 320, Industrial Area, Phase-1,
Panchkula, Pin-134113, Haryana, India.
Phone: +91-172-4194500

11th August, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex
Bandra (E), Mumbai – 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press release

Pursuant to regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we are enclosing herewith the press release issued by the Company on the unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026.

The Press Release will also be available on the website of the Company at www.innovacaptab.com.

This is for your information and record.

Thanking you,

Yours faithfully,
For Innova Captab Limited

NEEHARIKA SHUKLA
Digitally signed by NEEHARIKA SHUKLA
Date: 2026.08.11 19:11:18 +05'30'

Neeharika Shukla
Company Secretary and Compliance Officer

Encl.: As above

INNOVA CAPTAB LIMITED

Press Release

Innova Captab Limited reported strong results for Q1 FY27, with Revenue from Operations at ₹ 470.9 crores and EBITDA at ₹ 75.1 crores

Mumbai, 11th August, 2026: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its unaudited financial results for the quarter ended June 30th, 2026.

Consolidated Financial Summary:

Particulars (₹ Crs.)	Q1FY27	Q1FY26	*YoY (%)*	FY26
Revenue from operations	470.9	351.5	34.0%	1,630.0
EBITDA	75.1	56.6	32.7%	250.3
EBITDA Margin	*16.0%*	*16.1%*	*(10 bps)*	*15.4%*
PAT	44.1	31.0	42.3%	140.9

Q1FY27 vs. Q1 FY26 Performance:

- Revenue from Operations registered strong growth of 34.0% to ₹ 470.9 crores vs. ₹ 351.5 crores
- Recorded EBITDA growth of 32.7% to ₹ 75.1 crores vs. ₹ 56.6 crores. EBITDA margin for the quarter was 16.0%
- PAT for the quarter was ₹ 44.1 crores, registering growth of 42.3%. PAT margin was 9.4%

Commenting on the company's performance, Mr. Vinay Lohariwala, Managing Director, Innova Captab Limited, said "Innova Captab Limited delivered a strong start to FY27, with revenue and EBITDA growing by 34% and 33% YoY, respectively. The performance underscores the continued strength of our diversified business model, disciplined execution and sustained customer traction across both our CDMO Services & Products and Branded Generics businesses.

Growth during the quarter was supported by steady order flows, a broader product portfolio and deeper engagement with existing and new customers. Our focus on operational excellence, manufacturing efficiency and quality continues to strengthen our competitive positioning and enables us to meet the evolving requirements of domestic and international markets. Our Jammu facility is witnessing a steady ramp-up, supported by increasing business from existing customers as well as the onboarding of new clients.

We remain committed to strengthening our position as a trusted CDMO partner while expanding our branded generics footprint across key markets. With a clear strategic roadmap, disciplined capital allocation and timely execution, we are confident of sustaining growth while enhancing profitability and delivering long-term value for our stakeholders"

About Innova Captab Limited

Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 350 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA, PIC/s among others.
For more details, please visit www.innovacaptab.com

For more information, please contact:

Company Details	**Investor Relations Advisors**
Innova Captab Ltd. CIN: L24246MH2005PLC150371 **Mr. Lokesh Bhasin** **Email Id –** investors@innovacaptab.com www.innovacaptab.com	**Strategic Growth Advisors Pvt. Ltd.** CIN - U74140MH2010PTC204285 Ms. Shaily Patwa/ Mr. Shrikant Sangani Email - shaily.p@sgapl.net /shrikant.sangani@sgapl.net Mobile No – 9819494608 / 9619595686 www.sgapl.net